Multiple Cardiovascular Diseases or Risk Factors Increase the Severity of Coronavirus Disease 2019


Posted: 2021-09-24 19:00:00
. 2021 Sep 22. doi: 10.1253/circj.CJ-21-0684. Online ahead of print. Tomoyuki Yamada 1 2 , Taku Ogawa 1 3 , Kenta Minami 1 , Yusuke Kusaka 1 4 , Masaaki Hoshiga 5 , Akira Ukimura 1 5 , Takahide Sano 6 , Takeshi Kitai 7 , Taishi Yonetsu 8 , Sho Torii 9 , Shun Kohsaka 10 , Shunsuke Kuroda 11 , Koichi Node 12 , Yuya Matsue 13 14 , Shingo Matsumoto 15 Affiliations Expand Affiliations 1 Infection Control Center, Osaka Medical and Pharmaceutical University Hospital. 2 Department of Pharmacy, Osaka Medical and Pharmaceutical University Hospital. 3 Department of Microbiology and Infection Control, Osaka Medical and Pharmaceutical University. 4 Department of Anesthesiology, Osaka Medical and Pharmaceutical University. 5 Department of Cardiology, Osaka Medical and Pharmaceutical University. 6 Department of Cardiovascular Medicine, Toho University Graduate School of Medicine. 7 Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center. 8 Department of Interventional Cardiology, Tokyo Medical and Dental University. 9 Department of Cardiology, Tokai University School of Medicine. 10 Department of Cardiology, Keio University School of Medicine. 11 Department of Cardiovascular Medicine, Cleveland Clinic. 12 Department of Cardiovascular Medicine, Saga University. 13 Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine. 14 Cardiovascular Respiratory Sleep Medicine, Juntendo University Graduate School of Medicine. 15 Division of Cardiovascular Medicine, Department of Internal Medicine, Toho University Faculty of Medicine. Item in Clipboard Tomoyuki Yamada et al. Circ J. 2021. Show details Display options Display options Format . 2021 Sep 22. doi: 10.1253/circj.CJ-21-0684. Online ahead of print. Authors Tomoyuki Yamada 1 2 , Taku Ogawa 1 3 , Kenta Minami 1 , Yusuke Kusaka 1 4 , Masaaki Hoshiga 5 , Akira Ukimura 1 5 , Takahide Sano 6 , Takeshi Kitai 7 , Taishi Yonetsu 8 , Sho Torii 9 , Shun Kohsaka 10 , Shunsuke Kuroda 11 , Koichi Node 12 , Yuya Matsue 13 14 , Shingo Matsumoto 15 Affiliations 1 Infection Control Center, Osaka Medical and Pharmaceutical University Hospital. 2 Department of Pharmacy, Osaka Medical and Pharmaceutical University Hospital. 3 Department of Microbiology and Infection Control, Osaka Medical and Pharmaceutical University. 4 Department of Anesthesiology, Osaka Medical and Pharmaceutical University. 5 Department of Cardiology, Osaka Medical and Pharmaceutical University. 6 Department of Cardiovascular Medicine, Toho University Graduate School of Medicine. 7 Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center. 8 Department of Interventional Cardiology, Tokyo Medical and Dental University. 9 Department of Cardiology, Tokai University School of Medicine. 10 Department of Cardiology, Keio University School of Medicine. 11 Department of Cardiovascular Medicine, Cleveland Clinic. 12 Department of Cardiovascular Medicine, Saga University. 13 Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine. 14 Cardiovascular Respiratory Sleep Medicine, Juntendo University Graduate School of Medicine. 15 Division of Cardiovascular Medicine, Department of Internal Medicine, Toho University Faculty of Medicine. Item in Clipboard CiteDisplay options Display options Format Abstract Background: This study aimed to determine whether disease severity varied according to whether coronavirus disease 2019 (COVID-19) patients had multiple or single cardiovascular diseases and risk factors (CVDRFs).Methods and Results:COVID-19 patients with single (n=281) or multiple (n=412) CVDRFs were included retrospectively. Multivariable logistic regression showed no significant difference in the risk of in-hospital death between groups, but patients with multiple CVDRFs had a significantly higher risk of acute respiratory distress syndrome (odds ratio: 1.75, 95% confidence interval: 1.09-2.81). Conclusions: COVID-19 patients with multiple CVDRFs have a higher risk of complications than those with a single CDVRF. Keywords: Cardiovascular disease; Cardiovascular risk factors; Coronavirus disease.

参考サイト PubMed: covid-19



バイオクイックニュース日本語版:COVID-19特集

バイオクイックニュース日本語版
5月 08, 2020 バイオアソシエイツ

CytoDyn社、COVID-19薬のレロンリマブについて更新。 初期の結果は、Gilead社のレムデシビルに対する明確な優位性を示唆。(プレゼン全容)

レロンリマブ要約:- COVID-19 の三拍子揃った薬-レロンリマブはサイトカインストームを静め、免疫学的ホメオスタシスを回復し、ウイルス量を減らす-Gileadの抗ウイルス薬レムデシビルとGenetechの抗IL-6…

ゲスト 934人 と メンバー 7人 がオンラインです